Zhao Kewei, Wang Chunsheng, Shi Fang, Li Minghuan, Yu Jinming
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong University, Jinan, China.
Department of Radiation Oncology, Yantai Yuhuangding Hospital Affiliated to Qingdao University Medical College, Yantai, China.
Transl Cancer Res. 2020 Jun;9(6):3842-3853. doi: 10.21037/tcr-19-2849.
The hematological markers of systemic inflammation has been proved to be significantly associated with clinical outcomes in esophageal cancer. This retrospectively study was to evaluate the value of the hematological markers in predicting pathological complete response (pCR) and overall survival (OS) in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) who received neoadjuvant chemoradiotherapy (nCRT).
A total of 87 patients with newly diagnosed LA-ESCC were retrospectively analyzed. The pretreatment lymphocyte-monocyte ratio (LMR), neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) were selected as hematological markers.
After nCRT, 26 (29.9%) patients achieved pCR and 61 (70.1%) patients had non-pCR. The LMR was significantly higher in patients who achieved pCR compared to that in patients who did not achieve pCR (4.35±1.68 . 3.33±1.13, P=0.002). Based on the receiver operating characteristic (ROC) curve, the optimal cut off value of LMR that predicted pCR was 3.73 [area under the curve: 0.712; 95% confidence interval (CI): 0.594-0.830; P=0.002], with a sensitivity of 65.4% and specificity of 77.0%. The pCR rate of patients with LMR ≥3.73 was 53.1%, while the pCR rate of patients with LMR <3.73 was only 16.4% (P<0.001). The univariate and multivariate logistic regression analysis confirmed that LMR was an independent predictor of pCR [odds ratio: 5.093; 95% CI: 1.658-15.646; P=0.004]. However, in the prediction of OS, a multivariate Cox proportional hazard model revealed that only clinical stage [hazard ratio (HR): 1.970; 95% CI: 1.144-3.391; P=0.014] and pCR (HR: 0.469; 95% CI: 0.237-0.928; P=0.030) were independent prognostic factors.
Pre-treatment LMR may predict pCR in LA-ESCC patients who were treated with nCRT. Having pCR is an independent prognostic factor for prolonged survival.
全身炎症的血液学标志物已被证明与食管癌的临床结局显著相关。本回顾性研究旨在评估血液学标志物在预测接受新辅助放化疗(nCRT)的局部晚期食管鳞状细胞癌(LA-ESCC)患者的病理完全缓解(pCR)和总生存期(OS)方面的价值。
对87例新诊断的LA-ESCC患者进行回顾性分析。选择治疗前淋巴细胞与单核细胞比值(LMR)、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)以及全身免疫炎症指数(SII)作为血液学标志物。
nCRT后,26例(29.9%)患者达到pCR,61例(70.1%)患者未达到pCR。达到pCR的患者的LMR显著高于未达到pCR的患者(4.35±1.68 对3.33±1.13,P = 0.002)。根据受试者工作特征(ROC)曲线,预测pCR的LMR最佳截断值为3.73[曲线下面积:0.712;95%置信区间(CI):0.594 - 0.830;P = 0.002],敏感性为65.4%,特异性为77.0%。LMR≥3.73的患者的pCR率为53.1%,而LMR<3.73的患者的pCR率仅为16.4%(P<0.001)。单因素和多因素逻辑回归分析证实LMR是pCR的独立预测因子[比值比:5.093;95%CI:1.658 - 15.646;P = 0.004]。然而,在OS预测中,多因素Cox比例风险模型显示只有临床分期[风险比(HR):1.970;95%CI:1.144 - 3.391;P = 0.014]和pCR(HR:0.469;95%CI:0.237 - 0.928;P = 0.030)是独立的预后因素。
治疗前LMR可预测接受nCRT的LA-ESCC患者的pCR。达到pCR是延长生存期的独立预后因素。